Prediction of a major clinical response (BASDAI 50) to tumour necrosis factor alpha blockers in ankylosing spondylitis.
about
TNF-alpha inhibitors for ankylosing spondylitisComparison of performance of the Assessment of SpondyloArthritis International Society, the European Spondyloarthropathy Study Group and the modified New York criteria in a cohort of Chinese patients with spondyloarthritisClinical response to discontinuation of anti-TNF therapy in patients with ankylosing spondylitis after 3 years of continuous treatment with infliximabClinical Tools to Assess and Monitor SpondyloarthritisIntegrative structural biomechanical concepts of ankylosing spondylitis[Evaluation of performance of BASDAI (Bath Ankylosing Spondylitis Disease Activity Index) in a Brazilian cohort of 1,492 patients with spondyloarthritis: data from the Brazilian Registry of Spondyloarthritides (RBE)].Anti-TNF-alpha therapy in ankylosing spondylitis.First signs and symptoms of spondyloarthritis--data from an inception cohort with a disease course of two years or less (REGISPONSER-Early)Ankylosing spondylitis in iran; late diagnosis and its causes.Predictors of response to anti-TNF therapy in ankylosing spondylitis: results from the British Society for Rheumatology Biologics Register.Gene expression analysis of macrophages derived from ankylosing spondylitis patients reveals interferon-gamma dysregulationAdalimumab in ankylosing spondylitis: an evidence-based review of its place in therapy.Update on ankylosing spondylitis: current concepts in pathogenesis.Update on the treatment of ankylosing spondylitis.Spondyloarthritides: evolving therapiesSpontaneous, drug-induced, and drug-free remission in peripheral and axial spondyloarthritis.Predicting the outcome of ankylosing spondylitis therapyDiagnosis and management of ankylosing spondylitis.Effects of etanercept versus sulfasalazine in early axial spondyloarthritis on active inflammatory lesions as detected by whole-body MRI (ESTHER): a 48-week randomised controlled trialBaseline predictors of response and discontinuation of tumor necrosis factor-alpha blocking therapy in ankylosing spondylitis: a prospective longitudinal observational cohort study.First update of the international ASAS consensus statement for the use of anti-TNF agents in patients with ankylosing spondylitis.ASAS/EULAR recommendations for the management of ankylosing spondylitis.Prediction of major clinical response (ACR50) to infliximab in psoriatic arthritis refractory to methotrexate.Early response to adalimumab predicts long-term remission through 5 years of treatment in patients with ankylosing spondylitis.Predictive Factors of Clinical Response of Infliximab Therapy in Active Nonradiographic Axial Spondyloarthritis PatientsEarly referral recommendations for ankylosing spondylitis (including pre-radiographic and radiographic forms) in primary care.Evaluation of dose reduction versus standard dosing for maintenance of remission in patients with spondyloarthritis and clinical remission with anti-TNF (REDES-TNF): study protocol for a randomized controlled trialAnkylosing spondylitis: recent breakthroughs in diagnosis and treatmentPredictors of response to TNF antagonists in patients with ankylosing spondylitis and psoriatic arthritis: systematic review and meta-analysis.Performance of referral recommendations in patients with chronic back pain and suspected axial spondyloarthritis.Education improves referral of patients suspected of having spondyloarthritis by general practitioners: a study with unannounced standardised patients in daily practiceBoth baseline clinical factors and genetic polymorphisms influence the development of severe functional status in ankylosing spondylitisBone formation rather than inflammation reflects ankylosing spondylitis activity on PET-CT: a pilot studyBody mass index influences the response to infliximab in ankylosing spondylitisHow early should ankylosing spondylitis be treated with tumour necrosis factor blockers?Pharmaceutical Benefits Scheme criteria for the use of tumour necrosis factor-alpha inhibitors in the treatment of ankylosing spondylitis in Australia: are they evidence based?Developments and current pharmacotherapeutic recommendations for ankylosing spondylitis.Comparison of non-radiographic axial spondyloarthritis and ankylosing spondylitis patients--baseline characteristics, treatment adherence, and development of clinical variables during three years of anti-TNF therapy in clinical practice.A randomized, double-blind, placebo-controlled, sixteen-week study of subcutaneous golimumab in patients with active nonradiographic axial spondyloarthritisReview article: Altering the natural history of Crohn's disease--evidence for and against current therapies.
P2860
Q24186462-D03FFF91-D688-4B04-88BB-6BF7FC483273Q24604766-8D8DE4B0-631B-4359-BC5B-B803B46A85EEQ24816557-3454831E-4873-4301-B158-46EB9CC158E5Q26866120-7D1A2C08-5908-4168-A875-9451CF64783EQ28395076-7D38AA96-B1FB-4915-B260-5226ACD3CB59Q30881987-0740AE77-21D1-41FF-AB75-EF9CBD06940CQ33204138-492C3027-DE05-4297-9B40-0F7F933D1F39Q33408102-4F5EACC6-3F10-4982-8B0C-9E64641322A3Q33640595-E2DBE1D8-EBAF-4927-AE6F-3CD8E249005DQ33646340-476972AF-2A8C-4082-AC8D-A8B395799ECFQ33923744-6CA96709-DC5F-4054-BC64-9E2A453C4D08Q34449888-BF5B54F9-0AD0-4A36-AB59-8F1EF4A7BDA3Q34450732-66761B16-00CD-4F35-905A-307295ECB97CQ34592673-D302ECA7-A6CE-409A-9D1D-D81BB46EE374Q34613907-0104FB1E-8D11-4F93-A4A1-AE8DA63B97FAQ34894874-09463004-E034-4546-973C-D515CC54137FQ34905433-EC717373-7C66-418F-A157-29AFC6A52B53Q35039166-907F3ACE-74C5-4752-867B-0C70AFB29425Q35537104-D99B22D2-1DA3-40FA-86AB-28A493531628Q35557916-D2B98F9D-780D-4627-9452-43C3215DC1FEQ35636900-D6CBCCD5-5CB3-4115-97FC-9608F891F298Q35637012-1A60BBBD-5FD6-41F1-8AFC-EB8DE450F7B8Q35760136-6A90C7A4-7BBC-495F-B55A-1575F79FEC1DQ35896670-2A34B263-1B00-445F-B901-FA58F479BAC5Q35931041-64FA85FD-377B-4BC1-9060-D2E248E7C56CQ35940404-4A7E4A4D-97ED-4FF9-A404-4B0B9F669B83Q35986462-BCBE925E-5033-4F92-856E-40479D16B200Q36143588-A347FEB5-EBD2-42E0-9B59-BA76CC63799BQ36182383-A2366680-87D2-4785-A031-53AC9A4A20C8Q36204136-4D3AEE80-2426-4739-B524-7C8E0C3B2C48Q36215871-C33EEFE6-7B6F-432F-AF65-386BCE2A730BQ36229769-AA9EE4F4-90BB-4263-AC27-E718D404AC03Q36245785-DE632C62-0410-4912-9759-F57E8337C3A1Q36245977-75499936-00DF-4C20-9A48-CB0CB5F0FB69Q36292652-DA9590C1-BE2A-4695-A740-CAEAA8857EADQ36393852-1C51E39B-1878-4E50-A27E-290BF5A41C38Q36458447-AD188498-174A-4B88-9A2F-BB0D86952C14Q36477447-113E8967-CD27-40A7-B315-D593076C6A21Q36584217-F31120FF-036E-4DF2-982B-6797B9375493Q36710319-AB8018F9-C96E-4D9E-966C-AD04987CC736
P2860
Prediction of a major clinical response (BASDAI 50) to tumour necrosis factor alpha blockers in ankylosing spondylitis.
description
2004 nî lūn-bûn
@nan
2004 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի մարտին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
name
Prediction of a major clinical ...... ers in ankylosing spondylitis.
@ast
Prediction of a major clinical ...... ers in ankylosing spondylitis.
@en
type
label
Prediction of a major clinical ...... ers in ankylosing spondylitis.
@ast
Prediction of a major clinical ...... ers in ankylosing spondylitis.
@en
prefLabel
Prediction of a major clinical ...... ers in ankylosing spondylitis.
@ast
Prediction of a major clinical ...... ers in ankylosing spondylitis.
@en
P2093
P2860
P356
P1476
Prediction of a major clinical ...... ers in ankylosing spondylitis.
@en
P2093
P2860
P304
P356
10.1136/ARD.2003.016386
P407
P577
2004-03-22T00:00:00Z